| Abstrakt: |
The article focuses on a patent application submitted by Bristol-Myers Squibb Company, detailing methods for treating tumors through subcutaneous administration of anti-PD-1 or anti-PD-L1 antibodies. It describes a novel approach to enhance patient compliance by using subcutaneous delivery instead of traditional intravenous methods, which can be inconvenient and invasive. It also outlines various dosing regimens and formulations to optimize the treatment's efficacy and patient experience. |
